CIDP patients with IVIg treatment had significantly increased frequencies of CD19 + B cells compared to healthy controls and other CIDP patient treatment subgroups but CIDP patients with immunosuppressive treatment (Fig. 4B). This evidence concerns the gene CD19 and chronic inflammatory demyelinating polyradiculoneuropathy.